Headlands Technologies LLC Invests $1.04 Million in Maravai LifeSciences Holdings, Inc. $MRVI

Headlands Technologies LLC acquired a new position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 166,327 shares of the company’s stock, valued at approximately $1,038,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Royal Bank of Canada grew its stake in shares of Maravai LifeSciences by 49.0% during the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock valued at $27,000 after purchasing an additional 3,209 shares during the period. Barclays PLC boosted its holdings in shares of Maravai LifeSciences by 3.0% in the fourth quarter. Barclays PLC now owns 172,281 shares of the company’s stock worth $560,000 after buying an additional 5,057 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Maravai LifeSciences by 12.5% in the second quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock worth $112,000 after buying an additional 5,160 shares during the last quarter. Bank of New York Mellon Corp grew its position in Maravai LifeSciences by 2.7% during the first quarter. Bank of New York Mellon Corp now owns 343,643 shares of the company’s stock valued at $973,000 after buying an additional 8,955 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in Maravai LifeSciences by 121.1% during the second quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company’s stock valued at $43,000 after buying an additional 9,870 shares during the period. 50.25% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the completion of the transaction, the general counsel directly owned 360,767 shares of the company’s stock, valued at approximately $1,825,481.02. This represents a 6.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.49% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Wells Fargo & Company raised their target price on Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a report on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Wednesday, August 26th. Wall Street Zen cut Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. Two analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $6.25.

Maravai LifeSciences Trading Down 4.5%

MRVI stock opened at $7.30 on Wednesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.05 and a quick ratio of 2.98. Maravai LifeSciences Holdings, Inc. has a 1-year low of $2.29 and a 1-year high of $9.42. The business has a 50 day simple moving average of $6.70 and a two-hundred day simple moving average of $4.83. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -14.04 and a beta of 0.60.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. The firm had revenue of $51.44 million for the quarter, compared to the consensus estimate of $48.67 million. Research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.